NUVATION BIO INC (NUVB) Fundamental Analysis & Valuation

NYSE:NUVB • US67080N1019

Current stock price

4.49 USD
+0.04 (+0.9%)
At close:
4.51 USD
+0.02 (+0.45%)
After Hours:

This NUVB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NUVB Profitability Analysis

1.1 Basic Checks

  • NUVB had negative earnings in the past year.
  • NUVB had a negative operating cash flow in the past year.
  • NUVB had negative earnings in each of the past 5 years.
  • In the past 5 years NUVB always reported negative operating cash flow.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M -500M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -34.40%, NUVB is in line with its industry, outperforming 46.07% of the companies in the same industry.
  • NUVB has a Return On Equity (-66.93%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.4%
ROE -66.93%
ROIC N/A
ROA(3y)-50.55%
ROA(5y)-35.67%
ROE(3y)-67.31%
ROE(5y)-45.89%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Gross Margin of NUVB (85.22%) is better than 89.01% of its industry peers.
  • The Profit Margin and Operating Margin are not available for NUVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NUVB Health Analysis

2.1 Basic Checks

  • NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NUVB has been increased compared to 1 year ago.
  • The number of shares outstanding for NUVB has been increased compared to 5 years ago.
  • NUVB has a worse debt/assets ratio than last year.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 0.53, we must say that NUVB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.53, NUVB is in line with its industry, outperforming 48.17% of the companies in the same industry.
  • NUVB has a Debt/Equity ratio of 0.65. This is a neutral value indicating NUVB is somewhat dependend on debt financing.
  • The Debt to Equity ratio of NUVB (0.65) is worse than 71.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z 0.53
ROIC/WACCN/A
WACC9.47%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.95 indicates that NUVB has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.95, NUVB is doing good in the industry, outperforming 73.30% of the companies in the same industry.
  • A Quick Ratio of 6.81 indicates that NUVB has no problem at all paying its short term obligations.
  • The Quick ratio of NUVB (6.81) is better than 72.77% of its industry peers.
Industry RankSector Rank
Current Ratio 6.95
Quick Ratio 6.81
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NUVB Growth Analysis

3.1 Past

  • The earnings per share for NUVB have decreased strongly by -15.38% in the last year.
  • NUVB shows a strong growth in Revenue. In the last year, the Revenue has grown by 698.96%.
EPS 1Y (TTM)-15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)698.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%633.06%

3.2 Future

  • NUVB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
  • NUVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.11% yearly.
EPS Next Y18.49%
EPS Next 2Y24.62%
EPS Next 3Y24.3%
EPS Next 5Y16.39%
Revenue Next Year218.62%
Revenue Next 2Y124.5%
Revenue Next 3Y92.95%
Revenue Next 5Y67.11%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. NUVB Valuation Analysis

4.1 Price/Earnings Ratio

  • NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NUVB's earnings are expected to grow with 24.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.62%
EPS Next 3Y24.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NUVB Dividend Analysis

5.1 Amount

  • NUVB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUVB Fundamentals: All Metrics, Ratios and Statistics

NUVATION BIO INC

NYSE:NUVB (5/1/2026, 8:04:00 PM)

After market: 4.51 +0.02 (+0.45%)

4.49

+0.04 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)03-02
Earnings (Next)05-04
Inst Owners62.19%
Inst Owner Change-1.72%
Ins Owners17.69%
Ins Owner Change0.04%
Market Cap1.56B
Revenue(TTM)62.90M
Net Income(TTM)-204.63M
Analysts82.35
Price Target11.83 (163.47%)
Short Float %17.85%
Short Ratio11.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.85%
Min EPS beat(2)-20.68%
Max EPS beat(2)6.98%
EPS beat(4)3
Avg EPS beat(4)-2.98%
Min EPS beat(4)-20.68%
Max EPS beat(4)6.98%
EPS beat(8)4
Avg EPS beat(8)-19.33%
EPS beat(12)8
Avg EPS beat(12)-5.68%
EPS beat(16)11
Avg EPS beat(16)-1.47%
Revenue beat(2)2
Avg Revenue beat(2)52.22%
Min Revenue beat(2)9.96%
Max Revenue beat(2)94.49%
Revenue beat(4)4
Avg Revenue beat(4)489.2%
Min Revenue beat(4)9.96%
Max Revenue beat(4)1226.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)250%
EPS NQ rev (3m)104.29%
EPS NY rev (1m)1.89%
EPS NY rev (3m)5.1%
Revenue NQ rev (1m)-0.42%
Revenue NQ rev (3m)98.82%
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)16.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.82
P/FCF N/A
P/OCF N/A
P/B 5.11
P/tB 5.3
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.18
BVpS0.88
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.4%
ROE -66.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.22%
FCFM N/A
ROA(3y)-50.55%
ROA(5y)-35.67%
ROE(3y)-67.31%
ROE(5y)-45.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 480.39%
Cap/Sales 13.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.95
Quick Ratio 6.81
Altman-Z 0.53
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)178.4%
Cap/Depr(5y)175.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y18.49%
EPS Next 2Y24.62%
EPS Next 3Y24.3%
EPS Next 5Y16.39%
Revenue 1Y (TTM)698.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%633.06%
Revenue Next Year218.62%
Revenue Next 2Y124.5%
Revenue Next 3Y92.95%
Revenue Next 5Y67.11%
EBIT growth 1Y-27.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y22.04%
EBIT Next 5YN/A
FCF growth 1Y-39.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.98%
OCF growth 3YN/A
OCF growth 5YN/A

NUVATION BIO INC / NUVB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.


Can you provide the valuation status for NUVATION BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.


Can you provide the profitability details for NUVATION BIO INC?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.


What is the expected EPS growth for NUVATION BIO INC (NUVB) stock?

The Earnings per Share (EPS) of NUVATION BIO INC (NUVB) is expected to grow by 18.49% in the next year.